Valuation: Lotus Pharmaceuticals, Inc.

Market Cap 9.74M 8.43M 7.88M 7.2M 13.57M 929M 13.78M 92.38M 36.25M 465M 36.56M 35.76M 1.55B P/E 2009
3.88x
P/E 2010 4.84x
Enterprise Value 14.38M 12.45M 11.64M 10.64M 20.04M 1.37B 20.36M 136M 53.55M 686M 54M 52.83M 2.29B EV / Sales 2009
1.02x
EV / Sales 2010 0.95x
Free-Float
99%
Yield 2009 *
-
Yield 2010 -
Manager TitleAgeSince
Chief Executive Officer - -
Director TitleAgeSince
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+41.51%-18.92% - - 7.93M
-0.12%-1.12%+20.74%+71.50% 48.92B
-1.14%+9.22%+60.80%+124.81% 41.53B
-0.32%+0.21%-2.78%+17.02% 12.43B
+6.43%+5.40%+24.64%+82.96% 11.7B
-0.48%-0.38%+30.98%+137.44% 9.09B
+0.31%+7.45%+23.46%+38.06% 7.4B
+1.62%+3.49%+41.67%-13.45% 7.15B
+1.10%+2.29%+11.06%+184.02% 6.66B
+0.03%+8.55%-24.59%+30.34% 5.95B
Average +4.90%+3,738.35%+20.67%+74.75% 16.76B
Weighted average by Cap. +0.24%+5,024.32%+29.66%+84.23%

Financials

2009 2010
Net sales 57.82M 50.06M 46.79M 42.76M 80.59M 5.51B 81.85M 549M 215M 2.76B 217M 212M 9.19B 72.7M 62.93M 58.82M 53.76M 101M 6.93B 103M 690M 271M 3.47B 273M 267M 11.55B
Net income 16.43M 14.23M 13.3M 12.15M 22.9M 1.57B 23.26M 156M 61.18M 784M 61.7M 60.36M 2.61B 14.42M 12.49M 11.67M 10.67M 20.1M 1.38B 20.42M 137M 53.71M 688M 54.16M 52.98M 2.29B
Net Debt 5.29 4.58 4.28 3.92 7.38 504.89 7.49 50.23 19.71 252.59 19.88 19.44 841.25 4.65 4.02 3.76 3.44 6.48 443.18 6.58 44.09 17.3 221.71 17.45 17.07 738.42
Logo Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
-